Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Sloan

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Journal of Medicinal Chemistry|April 29, 2010
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesityLin Yan, Pei Huo, John S Debenham, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1John S Debenham, Christina B Madsen-Duggan, Richard B Toupence, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Plos Pathogens|April 16, 2016
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-LymphocytesR Brad Jones, Stefanie Mueller, Rachel O'Connor, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesityLinus S Lin, Thomas J Lanza, James P Jewell, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonistsHelen E Armstrong, Amy Galka, Linus S Lin, et al.
European Journal of Pharmacology|November 21, 2007
Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodentsLauren P Shearman, D Sloan Stribling, Ramon E Camacho, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodentsTung M Fong, Xiao-Ming Guan, Donald J Marsh, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Journal of Medicinal Chemistry|April 29, 2010
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesityLin Yan, Pei Huo, John S Debenham, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1John S Debenham, Christina B Madsen-Duggan, Richard B Toupence, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Plos Pathogens|April 16, 2016
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-LymphocytesR Brad Jones, Stefanie Mueller, Rachel O'Connor, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesityLinus S Lin, Thomas J Lanza, James P Jewell, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonistsHelen E Armstrong, Amy Galka, Linus S Lin, et al.
European Journal of Pharmacology|November 21, 2007
Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodentsLauren P Shearman, D Sloan Stribling, Ramon E Camacho, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodentsTung M Fong, Xiao-Ming Guan, Donald J Marsh, et al.
Pageof 19